Phase I Study of NBTXR3 Activated by Radiotherapy for Locally Advanced or Borderline Resectable Pancreatic Ductal Adenocarcinoma
The purpose of this phase I study is to evaluate the safety and feasibility of NBTXR3 activated by radiation therapy in patients with borderline- resectable or locally advanced pancreatic cancer.
Study ID: 2019-1001
Trial Phase: Phase I
Trial Sponsor: M.D. Anderson Cancer Center
Therapies Used in This Trial: NBTXR3